Drug intelligence / Profile preview

Nicopass

Development stage: Phase 2
Lead developer: Pierre Fabre
Modality: Small Molecules
Administration: Oral

Overview

**Nicopass** is a nicotine replacement therapy (NRT) brand consisting of sugar-free lozenges available in flavors such as fresh mint, eucalyptus, and liquorice mint, with strengths of 1.5 mg or 2.5 mg nicotine (as nicotine cation resin carboxylate complex). Developed by **Pierre Fabre Medicament**, it is indicated for the treatment of tobacco dependence by relieving nicotine withdrawal symptoms in adults wishing to quit smoking, including temporary abstinence or smoking reduction strategies. The lozenges dissolve slowly in the mouth over about 30 minutes for gradual nicotine absorption via the oral mucosa, with a maximum daily dose of 30 lozenges and recommended treatment duration not exceeding 12 months.[1][2][3][4][5][7]

Brand names: Nicopass

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on Nicopass.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicopass.

Explore the full profile